Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

NCT04909034 is registered in ClinicalTrials.gov with Microbio Co Ltd as lead sponsor.

NCT NCT04909034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04909034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Lead sponsor
Microbio Co Ltd
Phase
Not applicable
Overall status
Completed
Start date
August 20, 2021
Completion date
November 30, 2024
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iiib~iv